Cargando…
Drug delivery nanosystems for biomedical applications /
Drug Delivery Nanosystems for Biomedical Application reviews some of the most challenging nanosystems with different routes of delivery that are useful for specific drugs, from both efficacy and bioavailability points-of-view. The chapters explore how this area is developing, the present state of th...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam, Netherlands :
Elsevier,
[2018]
|
| Colección: | Micro & nano technologies.
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Front Cover; Drug Delivery Nanosystems for Biomedical Applications; Copyright; Contents; Contributors; Chapter 1: Drug delivery nanosystems-An introduction; 1.1 Foreword; 1.2 Different Forms of Drug Delivery Vehicles; 1.2.1 Colloidal Nanoparticles and Nanocapsules; 1.2.2 Nonspherical and Inorganic Nanoparticles; 1.2.3 Polymeric Micelles and Other Nanoparticles; 1.3 Classification of Drug Delivery Nanosystems; 1.4 Versatality to the Target Site; 1.5 Perspectives; References; Chapter 2: Blood compatibility of nanomaterials; 2.1 Introduction; 2.2 Blood Compatibility: Background
- 2.3 Macro-materials2.4 Nanomaterials; 2.4.1 Platelet Adhesion/Aggregation, Plasma Coagulation, Complement Activation, Hemolysis; 2.4.2 Protein Adsorption: The Corona; Acknowledgments; References; Chapter 3: Safety and toxicity concerns of nanosystems; 3.1 Introduction; 3.2 Nanoparticle Exposure; 3.2.1 Occupational Exposure; 3.2.2 Environmental Exposure; 3.2.3 Consumer Exposure; 3.3 Routes of Exposures; 3.3.1 Inhalation; 3.3.2 Transdermal Absorption; 3.3.3 Ingestion; 3.3.4 Injection/Parenteral Administration; 3.4 Bio-Nano Interactions-Cellular and Molecular Levels; 3.5 Nanoparticle Uptake
- 3.6 Protein Corona3.7 Membrane Integrity; 3.8 Cytoskeletal Arrangement; 3.9 Organellar Dysfunction; 3.10 Apoptosis; 3.11 Reactive Oxygen Species and Oxidative Stress; 3.12 Genotoxicity; 3.13 Conclusion; Acknowledgments; References; Chapter 4: Pharmaceutical perspectives of selection criteria and toxicity profiling of nanotheranostic agents; 4.1 Introduction; 4.2 Critical Gap That Nanotheranostics Fills in Therapeutics; 4.3 Features and Concerns of Nanoparticle for Nanotheranostic Design
- 4.3.1 Structural and Electronic Properties of Nanoparticles at Nanoscale and Its Influence on Biological Functions4.3.2 Macroscale Dispersibility Properties of Nanoparticles Influencing the Biological Functions; 4.3.3 Dissolution and Disintegration Properties of Nanoparticles Influencing Biological Action; 4.4 Importance of Developing a Need-Based Selection Criteria; 4.4.1 Nature and Properties of Target Site for Need-Based Selection Criteria; 4.4.2 Types of Nanoconstructs From a Need-Based Selection Criteria; 4.5 Safety Aspects of Theranostic Agents and Toxicity Profiling
- 4.5.1 Safety Aspects of Nanotheranostics From Biological Perspective4.5.2 Safety at Cellular Level; 4.5.3 Safety at Tissue Level; 4.5.4 Toxicity at the Level of Blood; 4.5.5 Safety at Organ Level; 4.5.6 Safety at Body Level; 4.5.7 Safety Aspects of Nanotheranostics From Nanotheranostic Perspective; Structure-dependent toxicities of nanotheranostics; Dose-dependent toxicity; Advancements in toxicity screening; Marketing perspectives and clinical applications; 4.6 Conclusion; Acknowledgment; References; Chapter 5: Nanosystems and antibacterial applications; 5.1 Introduction